OCUL
Ocular Therapeutix IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.83B
P/E Ratio
—
EPS
$-1.42
Beta
0.95
52W High
$16.44
52W Low
$6.21
50-Day MA
$8.98
200-Day MA
$11.10
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.
Fundamentals
| Revenue (TTM) | $51.95M |
| Gross Profit (TTM) | $-151.72M |
| EBITDA | $-265.69M |
| Operating Margin | -526.00% |
| Return on Equity | -54.80% |
| Return on Assets | -26.70% |
| Revenue/Share (TTM) | $0.28 |
| Book Value | $3.03 |
| Price-to-Book | 2.83 |
| Price-to-Sales (TTM) | 35.28 |
| EV/Revenue | 22.89 |
| EV/EBITDA | -6.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -22.40% |
| Shares Outstanding | $217.69M |
| Float | $215.41M |
| % Insiders | 2.81% |
| % Institutions | 90.27% |
Analyst Ratings
Consensus ($26.00 target)
4
Strong Buy8
BuyData last updated: 4/9/2026